With China's 15th Five-Year Plan (2026–2030) unlocking massive opportunities for global enterprises by prioritizing high-quality growth and domestic consumption, UK-based company Haleon is strengthening its commitment to this dynamic market with a £65 million ($86 million) investment in a new state-of-the-art oral health manufacturing site in Shanghai. This strategic expansion aims to capture surging demand in China's fast-growing tier-2 and tier-3 cities, where rising incomes and a heightened focus on "better daily health" are driving consumers toward  trustworthy brand products. 

As affirmed by Brian McNamara, CEO of Haleon, this move underscores Haleon's long-term confidence in China, aligning corporate growth with the nation's broader vision for health innovation and economic resilience.